Lexiscan(r) (regadenoson) Injection, Solution
Product Images NDC 51662-1448

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lexiscan(r) (regadenoson) (NDC 51662-1448). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse 1 (Adverse 1)

A data table comparing the incidence of different adverse effects between LEXISCAN and ADENOSCAN in clinical study populations. It lists symptoms such as dyspnea, headache, flushing, chest discomfort, angina pectoris or ST segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot with percentage values for each symptom in subjects receiving LEXISCAN and ADENOSCAN.*

FDA Label Image

Adverse 2 (Adverse 2)

A comparative data table showing cardiac rhythm or conduction abnormalities percentages for LEXISCAN and ADENOSCAN in evaluable subjects. Categories include overall rhythm abnormalities, PACs, PVCs, first-degree and second-degree AV blocks, other AV conduction abnormalities, and ventricular conduction abnormalities, with respective rates and counts for each drug.*

FDA Label Image

Adverse 3 (Adverse 3)

A data table comparing respiratory adverse reactions between LEXISCAN and placebo in Asthma and Chronic Obstructive Pulmonary Disease (COPD) cohorts. It presents percentages for overall respiratory adverse reactions, dyspnea, wheezing, and FEV1 reduction greater than 15%, divided by treatment and patient group.*

FDA Label Image

Adverse 4 (Adverse 4)

A data table presenting cardiac events and Holter/12-lead ECG abnormalities comparing two groups following exercise with LEXISCAN. It lists incidence percentages for ST-T depression, ST-T elevation, acute coronary syndrome, and myocardial infarction in Group 1 (3 minutes post exercise) and Group 2 (1 hour post exercise).*

FDA Label Image

Syringe Carton Labeling (Carton Labeling)

Lexiscan (regadenoson) injection 0.4 mg/5 mL (0.08 mg/mL) in a single-dose pre-filled syringe. The label indicates it is a pharmacologic stress agent for diagnostic use only, sterile, nonpyrogenic, preservative-free, and for intravenous use. Packaging instructions and the labeler, HF Acquisition Co LLC, DBA HealthFirst, are also visible.*

FDA Label Image

Clinical P 1 (Clinical P 1)

A data table comparing vital sign parameters between LEXISCAN (Regadenoson) and ADENOSCAN. It lists heart rate, systolic blood pressure, and diastolic blood pressure categories with corresponding percentages for each drug, indicating occurrences such as heart rate over 100 bpm, blood pressure increases, and decreases in mm Hg across two sample sizes (LEXISCAN N=1,337, ADENOSCAN N=678).*

FDA Label Image

Clinical P 2 (Clinical P 2)

Data table presenting vital sign parameters comparing two groups using LEXISCAN: Group 1 with LEXISCAN 3 minutes following exercise (N=575) and Group 2 with LEXISCAN 1 hour following exercise (N=567). Parameters include heart rate and blood pressure statistics, showing percentages of subjects exceeding or decreasing specific thresholds for heart rate, systolic, and diastolic blood pressures.*

FDA Label Image

Clinical S (Clinical S)

A data table comparing two studies on agreement rates between ADENOSCAN and LEXISCAN, showing agreement rates with standard errors, rate differences, and 95% confidence intervals for each study.*

FDA Label Image

Serialized Carton Labeling (Serialized Carton)

LEXISCAN (Regadenoson) injection, 0.08 mg/mL, single bolus dose prefilled syringe carton. The packaging indicates it is a pharmacologic stress agent for intravenous use only. Distributed by HF Acquisition Co LLC, DBA HealthFirst, Mukilteo, WA. The label also details storage instructions and syringe usage notes, including needle options.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient Regadenoson showing the molecular arrangement of atoms and bonds, including functional groups and a hydration component (H2O). This structure corresponds to Regadenoson, the active ingredient in LEXISCAN(R) injection solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.